Last reviewed · How we verify
Reference: Tazorac Cream, 0.05%
Tazorac Cream, 0.05% is a topical retinoid that works by promoting cell turnover and preventing the formation of comedones, thereby reducing acne severity.
Tazorac Cream, 0.05% is a topical retinoid that works by promoting cell turnover and preventing the formation of comedones, thereby reducing acne severity. Used for Acne vulgaris.
At a glance
| Generic name | Reference: Tazorac Cream, 0.05% |
|---|---|
| Also known as | Tazorac |
| Sponsor | G & W Laboratories Inc. |
| Drug class | Retinoid |
| Target | Retinoic acid receptors |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to retinoic acid receptors, which are involved in regulating cell growth and differentiation. This leads to an increase in the rate of cell turnover, which helps to unclog pores and reduce inflammation. Additionally, it prevents the formation of comedones, which are a key factor in the development of acne.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Dryness
- Redness
Key clinical trials
- A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis (PHASE3)
- Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reference: Tazorac Cream, 0.05% CI brief — competitive landscape report
- Reference: Tazorac Cream, 0.05% updates RSS · CI watch RSS
- G & W Laboratories Inc. portfolio CI